AlLergies

• Reduces systemic Th2 cytokines and improved respiratory function in asthma trials within 4 weeks

• Significantly improves allergic rhinitis symptoms and quality of life in children

• Modulates mast cell activation in gut mucosa to control hypersensitivity reactions

• Clinical trials show LP-33 strain significantly reduces allergic rhinitis symptoms and improves quality of life in 425 adults within 5 weeks

• LGG strain increases regulatory T cells and reduces eczema incidence by up to 32% in long-term studies

• Bifidobacterium strains improve asthma symptoms and reduce Th2 inflammatory markers within 4 weeks

• LGG increased regulatory T cells and anti-inflammatory IL-10 production in just 5 weeks, promoting immune tolerance

• LP-33 significantly improved allergy symptoms in 425 adults with grass pollen allergies when combined with antihistamines

• 20 billion CFU daily of LGG reduced eczema incidence by 23% short-term and 32% long-term compared to controls